Alvotech (ALVO) SEC Filings: History & Chart

Alvotech(ALVO)

Drug Manufacturers - Specialty & Generic · Luxembourg, LU

$6.11+0.66 (+12.11%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Alvotech

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.

Luxembourg, LU

1,279 employees

www.alvotech.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Lisa Graver

View full financials

Form	Filing Date	Accepted	Document
6-K	Oct 5, 2026	Oct 5, 2026	View filing
6-K	Aug 31, 2026	Aug 31, 2026	View filing
6-K	Aug 21, 2026	Aug 21, 2026	View filing
6-K	Aug 19, 2026	Aug 19, 2026	View filing
6-K	Jul 29, 2026	Jul 29, 2026	View filing
6-K	Jul 1, 2026	Jul 1, 2026	View filing
SC 13D/A	Jun 30, 2026	Jun 30, 2026	View filing
6-K	Jun 18, 2026	Jun 18, 2026	View filing
6-K	Jun 17, 2026	Jun 16, 2026	View filing
424B5	Jun 16, 2026	Jun 16, 2026	View filing
FWP	Jun 16, 2026	Jun 16, 2026	View filing
FWP	Jun 15, 2026	Jun 15, 2026	View filing
424B5	Jun 15, 2026	Jun 15, 2026	View filing
6-K	Jun 15, 2026	Jun 15, 2026	View filing
6-K	Jun 8, 2026	Jun 8, 2026	View filing
6-K	Jun 4, 2026	Jun 4, 2026	View filing
6-K	May 11, 2026	May 11, 2026	View filing
6-K	May 4, 2026	May 4, 2026	View filing
20-F	Mar 31, 2026	Mar 30, 2026	View filing
6-K	Mar 19, 2026	Mar 19, 2026	View filing
SC 13D/A	Mar 12, 2026	Mar 12, 2026	View filing
6-K	Feb 27, 2026	Feb 27, 2026	View filing
6-K	Feb 5, 2026	Feb 5, 2026	View filing
6-K	Feb 2, 2026	Feb 2, 2026	View filing
6-K	Jan 29, 2026	Jan 29, 2026	View filing
6-K	Jan 7, 2026	Jan 7, 2026	View filing
6-K	Jan 7, 2026	Jan 7, 2026	View filing
6-K	Jan 6, 2026	Jan 6, 2026	View filing
6-K	Jan 2, 2026	Jan 2, 2026	View filing
6-K	Dec 23, 2025	Dec 23, 2025	View filing

SEC Filings

Recent Filings